Drug Prices

A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation, “What drives health spending in the U.S. compared to other countries,” does not provide a full picture on health care spending in the U.S. while also downplaying the immense role that drug costs play in…

A new AHA report highlights the significant growth in expenses across labor, drugs, and supplies, as well as the impact that rising inflation is having on hospital prices.

Hospitals appreciate the support and resources that Congress have provided throughout the COVID-19 pandemic; however, additional support is needed to keep hospitals strong so they can continue to provide care to patients and communities.

In a statement submitted to the Senate Finance Committee for a hearing on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies.

AHA shares proposals to lower Medicare drug prices with congress.

Pending federal approval, Civica Rx, the nonprofit consortium of U.S. hospitals, plans to manufacture and distribute several generic insulins, continuing its mission to alleviate chronic shortages of inpatient drugs and reduce drug prices.

Drug companies raised prices faster than inflation for about half of all drugs covered by Medicare between July 2019 and July 2020, according to an analysis released last week by the Kaiser Family Foundation.

The Centers for Medicare & Medicaid Services Dec.

The administration issued an interim final rule requiring health plans to begin submitting annual information next year on prescription drug coverage and spending, including the most frequently dispensed and costliest drugs, and information on prescription drug rebates and their impact on premiums…

In addition to being based on a very small sample size, a recently published study on hospital costs for clinician-administered drugs under Medicare Part B does not provide direct insight as to what hospitals actually pay to acquire these drugs, writes Aaron Wesolowski, vice president of policy…